Skip to main content

01.03.2014 | Original Research

Efficacy and Safety of Vitex agnus-castus Extract for Treatment of Premenstrual Syndrome in Japanese Patients: A Prospective, Open-label Study

verfasst von: Mikio Momoeda, Hidetaka Sasaki, Eiko Tagashira, Masayuki Ogishima, Yuichi Takano, Kazunori Ochiai

Erschienen in: Advances in Therapy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

ABSTRACT

Introduction

Herbal medicine containing Vitex agnus-castus (VAC) extract is widely used by women with premenstrual syndrome (PMS) in Europe, however, in Japan, clinical evidence remains to be determined. This study attempted to investigate the efficacy and safety profiles of VAC extract in Japanese patients with PMS.

Methods

A multi-center, prospective, open-label, single-arm, phase 3 study was performed in Japanese women with PMS and aged 18–44 years. The patients received Prefemin® (Max Zeller Söhne AG, Romanshorn, Switzerland), containing 20 mg of VAC extract, once daily for three menstrual cycles. The efficacy profile was examined based on the intensity of ten PMS symptoms—irritability, depressed mood, anger, headache, bloating, breast fullness, skin disorder, fatigue, drowsiness, and sleeplessness—recorded by patients via a visual analog scale (VAS). In addition, the responder rate was calculated based on the total VAS score defined by the sum of the VAS scores of the first six symptoms mentioned above. Furthermore, physician’s global assessment (PGA) scores were recorded. Adverse events including vital signs and laboratory test values were monitored as safety evaluation.

Results

Sixty-nine patients received Prefemin®. After the first menstrual cycle, a statistically significant decrease in total VAS score was observed (P < 0.001), and the score continued to diminish for the following two cycles. Each of the ten symptom scores decreased significantly in this manner. In addition, the responder rate increased in a time-dependent manner; the rate at the third menstrual cycle was 91.0%, and almost all of the patients were without symptoms or exhibited only mild symptoms based on PGA. Eight patients exhibited non-serious adverse events, one of which was allergic dermatitis whose causal relationship with VAC was not ruled out.

Conclusion

VAC extract improved PMS symptoms in Japanese patients, with no substantial adverse events. This is the first study to report the effect of VAC extract in Japanese patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol. 2007;20:3–12.PubMedCrossRef Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol. 2007;20:3–12.PubMedCrossRef
2.
Zurück zum Zitat American College of Obstetricians and Gynecologists practice bulletin. Premenstrual syndrome. Int J Gynecol Obstet. 2001;73:183–91.CrossRef American College of Obstetricians and Gynecologists practice bulletin. Premenstrual syndrome. Int J Gynecol Obstet. 2001;73:183–91.CrossRef
3.
Zurück zum Zitat Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am. 2000;27:625–39.PubMedCrossRef Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am. 2000;27:625–39.PubMedCrossRef
5.
Zurück zum Zitat Blumenthal M, editor. Chaste tree fruit. In: The Complete German Commission E Monographs. Austin: American Botanical Council; 1998. p. 108. Blumenthal M, editor. Chaste tree fruit. In: The Complete German Commission E Monographs. Austin: American Botanical Council; 1998. p. 108.
7.
Zurück zum Zitat Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102:448–54.PubMedCrossRef Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102:448–54.PubMedCrossRef
8.
Zurück zum Zitat Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993;25:253–5.PubMedCrossRef Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993;25:253–5.PubMedCrossRef
9.
Zurück zum Zitat Wuttke W, Gorkow CH, Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew D, Rietbrock N, editors. Phytopharmaka: Forschung, Klinik und Anwendung. Darmstadt: Steinkopf; 1995. p. 81–91.CrossRef Wuttke W, Gorkow CH, Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew D, Rietbrock N, editors. Phytopharmaka: Forschung, Klinik und Anwendung. Darmstadt: Steinkopf; 1995. p. 81–91.CrossRef
10.
Zurück zum Zitat Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;16(169):575–81. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;16(169):575–81.
11.
Zurück zum Zitat Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch Womens Ment Health. 2006;9:209–12.PubMedCrossRef Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch Womens Ment Health. 2006;9:209–12.PubMedCrossRef
12.
Zurück zum Zitat Sagara Y, Kuwabara Y, Mizuno M. Epidemiological and diagnostic problem on premenstrual syndrome in Japan [in Japanese]. Obstet Gynecol Pract. 1991;41:1235–41. Sagara Y, Kuwabara Y, Mizuno M. Epidemiological and diagnostic problem on premenstrual syndrome in Japan [in Japanese]. Obstet Gynecol Pract. 1991;41:1235–41.
13.
Zurück zum Zitat Schellenberg R, Zimmermann C, Drewe J, Hoexter G, Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012;19:1325–31.PubMedCrossRef Schellenberg R, Zimmermann C, Drewe J, Hoexter G, Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012;19:1325–31.PubMedCrossRef
14.
Zurück zum Zitat Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ. 2001;322:134–7.PubMedCentralPubMedCrossRef Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ. 2001;322:134–7.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Berger D, Schaffner W, Schrader E, Meier B, Brattström A. Efficacy of Vitex agnus castus L. extract Ze440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264:150–3.PubMedCrossRef Berger D, Schaffner W, Schrader E, Meier B, Brattström A. Efficacy of Vitex agnus castus L. extract Ze440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264:150–3.PubMedCrossRef
16.
Zurück zum Zitat American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 3rd rev ed. Washington, DC: American Psychiatric Association; 1987. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 3rd rev ed. Washington, DC: American Psychiatric Association; 1987.
17.
Zurück zum Zitat Casper RF, Powell AM. Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales. Am J Obstet Gynecol. 1986;155:862–7.PubMedCrossRef Casper RF, Powell AM. Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales. Am J Obstet Gynecol. 1986;155:862–7.PubMedCrossRef
18.
Zurück zum Zitat Prefemin® Filmtabletten [package insert]. Romanshorn: Max Zeller Söhne AG; 2008. Prefemin® Filmtabletten [package insert]. Romanshorn: Max Zeller Söhne AG; 2008.
19.
Zurück zum Zitat Carmichael AR. Can Vitex agnus castus be used for the treatment of mastalgia? What is the current evidence? eCAM. 2008;5:247–50.PubMedCentralPubMed Carmichael AR. Can Vitex agnus castus be used for the treatment of mastalgia? What is the current evidence? eCAM. 2008;5:247–50.PubMedCentralPubMed
20.
Zurück zum Zitat Van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorder: a systematic review of clinical trials. Planta Med. 2013;79:562–75.PubMed Van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorder: a systematic review of clinical trials. Planta Med. 2013;79:562–75.PubMed
Metadaten
Titel
Efficacy and Safety of Vitex agnus-castus Extract for Treatment of Premenstrual Syndrome in Japanese Patients: A Prospective, Open-label Study
verfasst von
Mikio Momoeda
Hidetaka Sasaki
Eiko Tagashira
Masayuki Ogishima
Yuichi Takano
Kazunori Ochiai
Publikationsdatum
01.03.2014
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 3/2014
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-014-0106-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.